What Life Sciences Gets Right (and Misses) About AI
In the News
What Life Sciences Gets Right (and Misses) About AI
I’ve spent most of my career in life sciences, and like many in the field, I’ve seen how slow and cautious the industry can be when embracing new technology. It’s understandable. We work in a highly regulated space where patient safety is the highest priority. Still, viewing AI only through the lens of operational efficiency is limiting its full potential.
Other industries with just as much at stake have found ways to make AI work powerfully and transformatively. Industries like manufacturing, aerospace, finance and healthcare are built on complex systems, high risk and serious accountability, just like ours.
In manufacturing, companies use AI to predict when machines need maintenance, minimize downtime, track product quality and detect anomalies early. These applications are improving both operational efficiency and product reliability, and pharma is beginning to explore and, in some cases, use similar approaches in manufacturing medicines. They’re using sensors to track equipment performance in real time. Even in pharma, where some manufacturing environments already utilize real-time sensor tracking, there is an opportunity to extend those capabilities into labs and research settings where instrument performance monitoring is often overlooked.
In finance, AI supports fraud detection, risk assessment and even investment decisions. These systems handle massive volumes of data, adapt to evolving threats and meet constant regulatory scrutiny. The parallels to drug safety and supply chain security are striking, and areas like counterfeit drug detection, fraud detection in clinical trials and early identification of product imperfections remain underutilized by current AI tools.
In healthcare, pockets of innovation — like AI-driven diagnostics and personalized care models — are emerging in response to patient needs. Life sciences could build on this momentum by expanding how we apply AI to accelerate and enhance clinical trial outcomes in similarly responsive ways.
So, what limits the full potential of AI in life sciences? Fear.
Read the full article here.
Discover how EPAM delivers digital transformation, data-driven insights and compliance-ready solutions to the Life Sciences and Healthcare industries here.
